Ravulizumab
- Generic Name
- Ravulizumab
- Brand Names
- Ultomiris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1803171-55-2
- Unique Ingredient Identifier
- C3VX249T6L
- Background
Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking terminal complem...
- Indication
Ravulizumab is indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
...
- Associated Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis, Paroxysmal Nocturnal Haemoglobinuria (PNH), Thrombotic Microangiopathies
- Associated Therapies
- -
Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05274633
- Locations
- 🇮🇹
Clinical Trial Site, Salerno, Italy
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 190
- Registration Number
- NCT05133531
- Locations
- 🇵🇪
Clinica San Felipe, Lima, Peru
🇵🇭St Lukes Medical Center, Quezon City, Central Luzon, Philippines
🇨🇳Taichung Veterans General Hospital (VGHTC), Taichung City, Taiwan
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05131204
- Locations
- 🇺🇸
Regeneron Research Facility, Whittier, California, United States
BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT05116774
- Locations
- 🇬🇧
Investigative Site, London, United Kingdom
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04999020
- Locations
- 🇬🇧
Research Site, Salford, United Kingdom
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
- Conditions
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04743804
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Conditions
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04702568
- Locations
- 🇬🇧
Study Center, London, United Kingdom
Ravulizumab and COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04570397
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04564339
- Locations
- 🇬🇧
Research Site, Salford, United Kingdom
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
- Conditions
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04557735
- Locations
- 🇬🇧
Research Site, Newcastle Upon Tyne, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.